Literature DB >> 11394885

Hypoxia-inducible factor 1alpha and 1beta proteins share common signaling pathways in human prostate cancer cells.

H Zhong1, C Hanrahan, H van der Poel, J W Simons.   

Abstract

Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor consisting alpha and beta subunits. It is critically involved in cancer cell hypoxia adaptation, glycolysis, and angiogenesis. HIF-1beta is associated with HIF-1 functions as a dimerization partner of HIF-1alpha, and is on the other hand associated with carcinogenesis via dioxin signaling. Regulation of HIF-1beta protein expression was investigated in human prostate cancer (PCA) cells. HIF-1beta protein was expressed constitutively under nonhypoxic conditions in all human PCA cells tested, and was up-regulated by hypoxia, CoCl2, EGF, serum, or PMA in moderate levels. Compared to that of HIF-1alpha, the constitutive, serum-, EGF-, and PMA-increased HIF-1beta protein expression were also inhibited by selective PI3K or FRAP/TOR inhibitors but in higher doses. Hypoxia partially reversed the dose dependent inhibition of HIF-1beta. These results suggest that HIF-1alpha and beta share common signaling pathways for nuclear protein accumulation. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11394885     DOI: 10.1006/bbrc.2001.4981

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Montelukast inhibits hypoxia inducible factor-1α translation in prostate cancer cells.

Authors:  Caixia Tang; Hu Lei; Jinfu Zhang; Meng Liu; Jin Jin; Hao Luo; Hanzhang Xu; Yingli Wu
Journal:  Cancer Biol Ther       Date:  2018-05-08       Impact factor: 4.742

2.  Obesity promotes aerobic glycolysis in prostate cancer cells.

Authors:  David A Cavazos; Matthew J deGraffenried; Shruti A Apte; Laura W Bowers; Kaitlin A Whelan; Linda A deGraffenried
Journal:  Nutr Cancer       Date:  2014-09-29       Impact factor: 2.900

Review 3.  Hypoxia-inducible aryl hydrocarbon receptor nuclear translocator (ARNT) (HIF-1β): is it a rare exception?

Authors:  Markus Mandl; Reinhard Depping
Journal:  Mol Med       Date:  2014-05-27       Impact factor: 6.354

4.  Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation.

Authors:  YunJin Jung; Jennifer S Isaacs; Sunmin Lee; Jane Trepel; Zheng-Gang Liu; Len Neckers
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

Review 5.  mTOR signaling and drug development in cancer.

Authors:  Janet Dancey
Journal:  Nat Rev Clin Oncol       Date:  2010-03-16       Impact factor: 66.675

Review 6.  Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1).

Authors:  Dale G Nagle; Yu-Dong Zhou
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

7.  Regulation of the Warburg effect in early-passage breast cancer cells.

Authors:  Ian F Robey; Renu M Stephen; Kathy S Brown; Brenda K Baggett; Robert A Gatenby; Robert J Gillies
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

8.  Expression and significance of PTEN, hypoxia-inducible factor-1 alpha in colorectal adenoma and adenocarcinoma.

Authors:  Ying-An Jiang; Li-Fang Fan; Chong-Qing Jiang; You-Yuan Zhang; He-Sheng Luo; Zhi-Jiao Tang; Dong Xia; Ming Wang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

Review 9.  Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.

Authors:  Yesid Alvarado; Monica M Mita; Sushma Vemulapalli; Devalingam Mahalingam; Alain C Mita
Journal:  Target Oncol       Date:  2011-05-04       Impact factor: 4.864

10.  Loss of HIF-1α in macrophages attenuates AhR/ARNT-mediated tumorigenesis in a PAH-driven tumor model.

Authors:  Nina Henke; Nerea Ferreirós; Gerd Geisslinger; Martina G Ding; Silke Essler; Dominik C Fuhrmann; Theresa Geis; Dmitry Namgaladze; Nathalie Dehne; Bernhard Brüne
Journal:  Oncotarget       Date:  2016-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.